CTLA4 and hepatocellular carcinoma: Dual checkpoint inhibition with durvalumab (PD-L1 inhibitor) and tremelimumab (CTLA-4 inhibitor) has been evaluated in unresectable hepatocellular carcinoma (HCC) through a phase 1/2 study followed by a confirmatory phase 3 trial (Table 6).